BA
NBIX icon

BlackRock Advisors’s Neurocrine Biosciences NBIX Stock Holding History

BlackRock Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$23.9M Sell
616,972
-326,218
-35% -$14.8M 0.02% 492
2016
Q3 		$47.8M Sell
943,190
-17,066
-2% -$850K 0.05% 323
2016
Q2 		$43.6M Sell
960,256
-57,627
-6% -$2.65M 0.04% 333
2016
Q1 		$40.3M Sell
1,017,883
-51,416
-5% -$2.04M 0.04% 364
2015
Q4 		$60.5M Buy
1,069,299
+235,700
+28% +$12M 0.06% 283
2015
Q3 		$33.2M Sell
833,599
-45,036
-5% -$2.18M 0.04% 393
2015
Q2 		$42M Buy
878,635
+86,281
+11% +$3.66M 0.04% 342
2015
Q1 		$31.5M Sell
792,354
-114,481
-13% -$4.1M 0.03% 425
2014
Q4 		$20.3M Sell
906,835
-38,576
-4% -$731K 0.02% 547
2014
Q3 		$14.8M Sell
945,411
-92,418
-9% -$1.38M 0.01% 660
2014
Q2 		$15.4M Sell
1,037,829
-26,171
-2% -$369K 0.01% 655
2014
Q1 		$17.1M Buy
1,064,000
+1,019,904
+2,313% +$17.4M 0.02% 603
2013
Q4 		$412K Buy
44,096
+2,863
+7% +$27.9K ﹤0.01% 2170
2013
Q3 		$467K Buy
41,233
+1,632
+4% +$22.4K ﹤0.01% 1961
2013
Q2 		$530K Buy
+39,601
New +$486K ﹤0.01% 1783

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's NBIX Position: Q4 2016 in Review

BlackRock Advisors reduced its Neurocrine Biosciences (NBIX) stake by 35% in Q4 2016, selling an estimated $14.8M and leaving 616,972 shares worth $23.9M. The position accounts for 0.02% of the portfolio, ranked #492.

BlackRock Advisors first reported a position in NBIX in Q2 2013 and has held it in 15 quarters since. The position peaked at $60.5M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • BlackRock Advisors held 616,972 shares of Neurocrine Biosciences worth $23.9M as of Q4 2016.
  • BlackRock Advisors sold 326,218 Neurocrine Biosciences shares in Q4 2016, an estimated $14.8M.
  • Neurocrine Biosciences made up 0.02% of BlackRock Advisors's portfolio in Q4 2016, its #492 holding.
  • BlackRock Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Neurocrine Biosciences position peaked at $60.5M in Q4 2015.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.